Skip to main content

CS Group (OTCQB: CSDX) Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene Products

Written by Customer Service on . Posted in Public Companies.

CHEYENNE, Wyo., Jan. 29, 2026 (GLOBE NEWSWIRE) — CS Diagnostics Corp. (OTCQB: CSDX), a medical technology and hygiene solutions company, today announced the confirmation of strategic manufacturing partnerships with Emirate Wet Wipes LLC that accelerate the Company’s transition into full commercial production ahead of the global launch of MEDUSA SDP, its next-generation medical-grade wet wipes and liquid disinfectant hygiene products designed for healthcare, institutional, and consumer markets.

MEDUSA SDP

Under the agreements, Emirate Wet Wipes LLC has been contracted to manufacture the MEDUSA SDP disinfectant wet wipes product line, while Gulf Centre Group Factory will produce bulk liquid hygiene and disinfectant formulations, including 500ml bottles and 5-liter commercial formats. These partnerships provide scalable manufacturing capacity, quality-controlled production, and compliance with regional and international health, safety, and medical manufacturing standards, supporting distribution across hospitals, clinics, retail chains, and e-commerce platforms.

Management stated that securing dedicated manufacturing partners represents a major commercialization milestone, moving MEDUSA SDP from development into revenue-ready production. The partnerships position CS Diagnostics to meet near-term global demand, support international distribution, and maintain operational flexibility as the Company expands across infection control, hospital hygiene, disinfectant products, and medical sanitation markets.

The Company noted that MEDUSA SDP is designed to address rising demand for infection prevention solutions, hospital-acquired infection reduction, and everyday hygiene products, aligning with long-term healthcare spending trends and increased regulatory focus on sanitation, public health, and environmental safety.

“Securing these strategic manufacturing partnerships is a pivotal step in advancing MEDUSA SDP from development into full-scale commercial production,” said Mohammad Essayed, Chief Financial Officer of CS Diagnostics Corp. “By aligning with experienced, quality-driven manufacturers, we are establishing the operational foundation needed to meet rising global demand for infection prevention and hygiene solutions. These agreements accelerate our timeline toward international launch and position CS Diagnostics to deliver scalable, compliant, and medically trusted products across healthcare, institutional, and consumer markets worldwide.”

About CS Diagnostics Corp

CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology company advancing a dual-focus platform across infection control and oncology, targeting high-priority global healthcare markets. The Company’s portfolio includes MEDUSA, a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations for institutional and consumer use, and CS Protect-Hydrogel, a tissue spacer designed to protect healthy organs during prostate cancer radiotherapy. CSDX is progressing through key commercialization milestones, including strategic manufacturing partnerships, a multi-region launches across the GCC and Europe, diversified B2B and B2C distribution channels, global logistics agreements, and a growing intellectual property and regulatory roadmap. With plans to introduce biodegradable, dissolving hygiene products and expand internationally.

Forward-Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company’s or any third party’s ability to execute and implement future plans, and the occurrence of unexpected events.

Actual results achieved may vary from the information provided herein because of numerous known and unknown risks, uncertainties, and other factors.

For further information, please visit https://medusa-sdp.com/en/

or contact

Mohammad Essayed

Email: info@csdcorp.us

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/01e72f7d-c962-4210-bd49-fb5baa15be48

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.